Blueprint Medicines (BPMC) Misses Q4 EPS by 2c

Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($2.65), $0.02 worse than the analyst estimate of ($2.63). Revenue for the quarter came in at $38.78 million versus the consensus estimate of $34.16 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance